1. Introduction {#s0005}
===============

Anabolic androgenic steroids (AAS) comprise a large category of synthetic derivatives of the male sex hormone testosterone widely used for cosmetic or ergogenic purposes ([@bb0145], [@bb0175], [@bb0160]). In addition to the performance enhancing and tissue building properties, AAS is associated with a wide range of symptoms, including aggression, violence and impulsive behaviors ([@bb0265], [@bb0360]). While positive effects of AAS on mood, such as transient euphoria and hypomania, have been reported early in the course of AAS use ([@bb0355]), anxiety, impulsivity, marked irritability and aggression is commonly manifested after long-term use ([@bb0115], [@bb0265], [@bb0290], [@bb0360]). Moreover, emerging evidence suggests that prolonged AAS use is associated with cognitive impairments including self-reported memory ([@bb0125], [@bb0350]), working memory and visuospatial abilities ([@bb0180], [@bb0185]).

Whereas the exact mechanisms of the adverse consequences of AAS use are unclear, they are likely partly reflecting disruptions of brain networks implicated in emotional and cognitive regulation. AAS readily passes the blood-brain barrier and affect central nervous system function. AAS binds to cytoplasmic androgen receptors ([@bb0150]), whereby the bound receptor is translocated into the nucleus where it binds to specific response elements in target genes and triggers DNA transcription and protein synthesis ([@bb0135], [@bb0200]). Androgen receptors are abundantly expressed in the amygdala, hippocampus, brain stem, hypothalamus, and cerebral cortex ([@bb0210], [@bb0280], [@bb0320]), implicating a wide range of functions, including regulation of emotion and cognition.

Commonly, AAS is administrated in cycles lasting for 8--16 weeks interspersed with drug-free intervals. During cycles a variety of AAS compounds are usually co-administered known as "stacking" with doses exceeding therapeutic levels by 5--100-fold in males \[7--9\], thereby generating highly non-physiological levels of endogenous and synthetic testosterone, with adverse effects on brain function ([@bb0065], [@bb0250]). Whereas some users ingest AAS only a few times during a lifetime, others develop a dependency syndrome, with sustained use despite adverse effects ([@bb0170]). The range and severity of the behavioral consequences increase with the severity of abuse ([@bb0260]). Exogenous AAS administration suppresses the hypothalamic-pituitary-testicular (HPT) axis, causing decreased endogenous testosterone production in males (39, 40). Cycles are used with the rationale that the HPT axis may recuperate during AAS-free intervals, restoring normal endogenous testosterone production ([@bb0305]). Thus, classical AAS administration results in substantial fluctuations of endogenous and synthetic testosterone throughout the cycle. Such hormonal fluctuations likely influence brain functions, and might explain AAS induced alterations in mood and behavior ([@bb0285], [@bb0350]).

Only one previous study has investigated functional brain networks as measured using functional MRI (fMRI) after prolonged AAS use. Using a seed-based approach targeting amygdala connectivity, it was found that resting-state coupling between the right amygdala and frontal, striatal, limbic, hippocampal, and visual cortical areas, respectively, was significantly lower in 7 users compared to 9 non-users ([@bb0185]). Further, a recent meta-analysis of fMRI activation studies revealed significant amygdala foci both after testosterone administration and in endogenous testosterone studies ([@bb0120]), and higher endogenous testosterone levels have been linked to attenuated resting-state amygdala-prefrontal coupling in adolescents ([@bb0270]), and in healthy males during a social approach-avoidance task ([@bb0375]), and intranasal testosterone reduced amygdala coupling with the orbitofrontal cortex in females ([@bb0365]).

Supraphysiological doses of AAS may cause apoptotic effects on a variety of cell types including neurons ([@bb0025], [@bb0060], [@bb0075], [@bb0085], [@bb0255]). In an overlapping sample, prolonged AAS use was associated with smaller gray matter, cortical and putamen volumes and thinner cortex, with stronger effects with increasing exposure, also in users without any other substance abuse ([@bb0035]). Summarized, converging evidence suggests that prolonged AAS use with supraphysiological doses is associated with both structural and functional brain alterations. However, available neuroimaging studies of AAS users are rare and limited by small samples sizes.

The aim of the current study was to test the effects of sustained AAS use on resting-state functional connectivity in a sample of male long-term AAS users and non-users. After rigorous denoising of the individual datasets to minimize the impact of motion and other artifacts, spatial maps constituting the nodes in the functional brain network and their associated time-series were estimated using spatial group independent component analysis (ICA) and dual regression. We defined the brain connectivity indices as the between-node partial temporal correlations, yielding a node-by-node correlation matrix for each dataset, where each node pair is referred to as an edge in the network. Next, we tested for associations between AAS status (current user, previous user or control) and connectivity strength using edgewise analysis. In order to further characterize the clinical sensitivity, we tested for associations with AAS dependency, lifetime exposure and AAS cycle state (on vs. off). Since elevated testosterone to epitestosterone (T/E) ratio may indicate use of testosterone, we tested for associations between connectivity and T/E ratios in the full sample (n = 142).

Based on existing evidence reviewed above, we anticipated that discriminative connections would implicate regions according to the anatomical distribution of androgen receptors, including the amygdala, hippocampus, and brain stem, and their synchronization with cortical nodes ([@bb0210], [@bb0280], [@bb0320]). In particular, due to the characteristic emotional consequences of AAS use, and converging neuroimaging evidence ([@bb0185], [@bb0270], [@bb0365], [@bb0375]), we expected group differences in amygdala connectivity and in brain network nodes involved in cognitive and emotional regulation, which would also be sensitive to the severity of dependence and total exposure.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

[Table 1](#t0005){ref-type="table"} summarizes demographic and clinical characteristics of the sample. Males engaged in heavy resistance strength training who were either current or previous AAS users reporting at least one year of cumulative AAS exposure (summarizing on-cycle periods) or who had never tried AAS or equivalent doping substances were recruited through webpages and forums targeting people interested in heavy weight training, bodybuilding, and online forums (open and closed) directly addressing steroid use. In addition, posters and flyers were distributed on select gyms in Oslo. In the recruitment information the study aim was explicitly stated. Prior to enrollment all participants received an information brochure with a complete description of the study. The study was approved by the Regional Committees for Medical and Health Research Ethics South East Norway (REC) (2013/601), all research was carried out in accordance with the Declaration of Helsinki, and written informed consent was collected from all subjects. Participants were compensated with 1000 NOK (approx. 125 USD). The sample is partly overlapping with the one described in detail in Bjørnebekk et al. ([@bb0035]). Here, we were primarily interested in brain connectivity alterations related to AAS-induced hormonal fluctuations. Thus, for the group analyses participants were divided into current, previous or a control group that in addition to self-reports were confirmed by the doping analyses. Participants failing to meet these strict group definitions were excluded from the group analyses, but were included in analyses testing for associations with T/E ratio across groups.

Resting-state fMRI data was obtained from 151 individuals, including 82 previous or current AAS users and 69 non-users based on self-reports. Of the 69 non-using *controls* one was excluded due to neuroradiological findings, one because he failed to match criteria for strength training (see [@bb0035] for details). In addition, three participants were excluded due to missing urine samples and five for having T/E ratios \> 4 (range 4.3--8.4), which might indicate administration of testosterone, yielding 59 participants in this group. Among the 82 AAS users with rFMRI data, two subjects were excluded due to less than a year of accumulated use, and two due to missing urine sample. The remaining 78 datasets comprised 58 *current users* and 20 *previous users*. Among the 58 *current users* reporting AAS use within the past 12 months eight were excluded due to a negative AAS test, yielding 50 current users. Among the 20 *previous users* with a self-reported history of AAS use in the past (\> 12 months prior to scanning) four were excluded due to traces of AAS or testosterone use in the urine, yielding 16 previous users. Supplemental Table 1 provides group summary stats and comparison on use characteristics for current, previous and excluded users. Material and methods used to assess AAS use, medical history, AAS dependence, verbal IQ, alcohol and drug use, mood and problem behavior are summarized in the Supplement.

2.2. Doping analysis {#s0020}
--------------------

Urine samples were collected at the same visit as the cognitive testing and analyzed for AAS and narcotics by gas chromatography and mass spectrometry at the WADA accredited Norwegian Doping Laboratory at Oslo University Hospital ([@bb0140]). Stimulants were analyzed by liquid chromatography and mass spectrometry.

Briefly, the criteria used to determine the use of AAS or testosterone are 1) urine samples positive for AAS compounds 2) a T/E ratio \> 4 as has been applied by World Anti-Doping Agency as a population based criteria for samples requiring further analysis by isotope ratio mass spectrometry (IRMS) or follow up to indicate testosterone abuse ([@bb0110]). When applying this criterion in research and routine analyses, cases of naturally occurring T/E ratios above 4 appear ([@bb0235]), and sometimes a stricter T/E ratio is preferred ([@bb0140]). Supplemental Fig. 1 and Supplemental Table 2 provides a summary of the frequency of the specific anabolic-androgenic steroids found in the urine sample, and Supplemental Table 3 summarizes the most popular compounds based on self-reports.

2.3. MRI acquisition {#s0025}
--------------------

MRI scans were obtained on a Siemens Skyra 3T scanner with a 24-channel head coil at Oslo University Hospital. We acquired structural MRI with a T1-weighted 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence, with the following parameters (TR: 2300 ms; TE: 2.98 ms; FA: 8°; voxel size: 1 × 1 × 1 mm; 176 sagittal slices) and fMRI data with a T2\*-weighted 2D gradient echo-planar imaging sequence (EPI) with 150 volumes (TR: 2390 ms; TE: 30 ms; FA: 90°; voxel size: 3 × 3 × 3 mm; 43 axial slices). Participants were instructed to keep their eyes open.

2.4. MRI processing and network estimation {#s0030}
------------------------------------------

For fMRI analysis we used the FMRI Expert Analysis Tool (FEAT) from the FMRIB Software Library (FSL) ([@bb0330]). The pipeline included motion correction (MCFLIRT), spatial smoothing (full width at half maximum of 6 mm), grand-mean intensity normalisation of the entire 4D dataset by a single multiplicative factor, high-pass temporal filtering (Gaussian-weighted least-squares straight line fitting, sigma = 45 s), and single-session independent component analysis (ICA) using MELODIC ([@bb0030])

We used FIX (ICA-based Xnoisefier ([@bb0315])), to identify and remove noise components on an individual level using a machine learning approach with a standard training set (threshold: 20). FIX was recently shown to outperform several different methods for data cleaning ([@bb0300])). Supplemental Fig. 2 shows average temporal signal-to-noise ratio (tSNR) ([@bb0310]) before and after FIX, and details regarding group differences are reported in the Supplement.

We extracted brain masks from the T1-weighted volumes using Freesurfer ([@bb0095]), used for registration to standard space using FLIRT ([@bb0155]) with boundary-based registration (BBR, ([@bb0105])) and FNIRT ([@bb0010]).

After registration, we employed group independent component analysis using MELODIC including all datasets by mean of a group-PCA technique ([@bb0340]). Automated model order selection yielded 47 components. Next, for each subject we estimated individual time series and component spatial maps using dual regression ([@bb0090]). Per recommendations ([@bb0205]), based on the component spatial maps and the frequency spectrum of the time series, we identified six noise components and regressed the time-series from these out of the remaining components. Next, we excluded another 11 components of which spatial maps were not corresponding to any interpretable neuronal origin or were outside the mask. The remaining 30 components constituted the nodes in subsequent network analyses, and the corresponding 435 temporal partial correlations between each component pairs formed the edges (connections) of the full network. As in previous studies ([@bb0195], [@bb0190], [@bb0325]), for each subject, we computed the regularized partial correlations ([@bb0335]) with automated individual estimation of regularization strength ([@bb0215]).

2.5. Statistical analysis {#s0035}
-------------------------

We assessed effects of AAS use on between-node connectivity by comparing current users, previous users and controls using analysis of covariance (ANCOVA) on each network edge, covarying for age. We corrected for multiple comparisons using Bonferroni correction across all 435 edges (adjusted alpha = 0.05/435). Next, in any edges showing significant effects of group, we tested for associations with dependency, life time exposure, and cycle state using ANCOVAs covarying for age (see Supplemental Information for details). To assess the relative importance of each node in distinguishing between groups, we calculated the eigenvector centrality of each node based on the edge-wise F-values from the group ANCOVA. A high centrality indicates altered connectivity with several other nodes, indicating a relative importance of this node in discriminating between groups, regardless of the significance threshold applied on the edge level.

To control for the possible influence of general cognitive function, aspects of mental health, alcohol and drug use on between-node connectivity, we conducted additional analyses where IQ, weekly alcohol consumption and the ASEBA ASR T-scores for anxious/depressed syndrome, drug use, attention problem and total problems were included as additional covariates (one at a time). Also, we conducted analyses where participants with traces of narcotics in the urine were excluded, in order to reassure that the findings were not a result of the use of narcotics. Finally, we assessed the relations between T/E ratio and edge strengths by Spearman\'s Rho correlations (T/E ratio distribution was positively skewed) across the full sample (n = 142).

3. Results {#s0040}
==========

3.1. Edgewise connectivity {#s0045}
--------------------------

[Fig. 1](#f0005){ref-type="fig"}A shows the results from the edgewise ANCOVA testing for differences between current AAS users (n = 50), previous AAS users (n = 16) and controls (n = 59). 49 (11.3%) of the edges showed nominal (p \< 0.05, uncorrected) and two edges showed significant (p \< 0.05, Bonferroni corrected) group effects. The two significant edges comprised the connections between the default mode network (DMN) and the amygdala (F = 10.2, p \< 8e − 05), and between the dorsal attention network (DAN) and a node encompassing the superior and inferior frontal gyrus (SFG/IFG) and the anterior portions of the anterior cingulate cortex (ACC) (F 9.8, p \< 1e − 04), both indicating reductions in functional connectivity in current AAS users compared to both non-users (t \> 4.0, p \< .1e − 04) and previous users (t \> 2.1, p \< 0.03), yet no difference between previous users and controls (t \< 0.97, p \> 0.33). [Fig. 1](#f0005){ref-type="fig"}B--C illustrates the corresponding connectivity patterns for both edges. The findings were replicated in analyses excluding participants with traces of narcotics in the urine, or with concurrent substance abuse. Including IQ, drug use, alcohol consumption, symptoms of anxiety and depression, attention problems and ASR total problem scores in the statistical models only marginally influenced the findings (Supplemental Table 4).

Supplemental Fig. 3 shows the EC value per node, reflecting a nodewise summary measure of effect size on tests for differences between current users, previous users and controls. The nodes showing strongest overall centrality were IC22 (SFG/IFG/ACC) and IC16 (DAN).

[Fig. 2](#f0010){ref-type="fig"}A splits current AAS users into individuals with (n = 27) and without (n = 23) dependence. Whereas the difference between dependent and non-dependent users was not significant in the DMN-amygdala edge, there was a clear pattern of controls \> non-dependent users \> dependent users in the DAN-SFG edge, with dependent users significantly different both from non-dependents users (t = 2.6, p = 0.01) and controls (t = 5.1, p = 2e − 06).

[Fig. 2](#f0010){ref-type="fig"}B splits the current AAS users according to their lifetime exposure (low dose: n = 15, medium dose: n = 17, high dose: n = 17). Both edges revealed a clear dose effect. There was a nominal significant difference between low dose and medium dose in the DMN-amygdala edge (t = 2.7, p = 0.013) and close to significance for low vs. high dose (t = 2.0, p = 0.054). Controls were significantly different from medium and high dose lifetime exposure groups. The DAN-SFG edge revealed a striking connectivity pattern of low dose \> medium dose \> high dose, although only differences between controls and any of the dose groups were significant.

[Fig. 2](#f0010){ref-type="fig"}C splits current users into those currently off cycle (n = 15) and those currently on cycle (n = 29), revealing a pattern of off cycle \> on cycle in mean connectivity. For the DMN-amygdala edge, controls significantly differed from current users on cycle (t = 4.0, p = 1e − 04) but not off cycle (t = 1.5, p = 0.13). For the DAN-SGF edge, controls differed from users on (t = 4.6, p = 1e − 05) and off cycle (t = 2.9, p = 0.005).

Finally, we assessed associations between T/E ratio and connectivity in the two main edges across the full sample (n = 142), independent of group assignment. [Fig. 3](#f0015){ref-type="fig"}A--B reveals decreased connectivity with increasing T/E, both for DMN-amygdala (rho = − 0.24, p = 4e − 03) and DAN-SFG (rho = − 0.32, p = 1e − 04). Supplemental Fig. 4 illustrates that the negative association persists across the full T/E span.

3.2. tSNR and motion as potential confounders {#s0050}
---------------------------------------------

In addition to denoising individual fMRI datasets using FIX ([@bb0315]), we tested if effects of AAS remained when including tSNR and motion as additional covariates in the statistical models. Briefly, whereas effect sizes were somewhat reduced, both edges still showed significant group effects (DMN-amygdala: F = 6.8, p = 0.002, DAN-SFG: 6.6, p = 0.001) when accounting for tSNR and motion.

4. Discussion {#s0055}
=============

In the largest functional neuroimaging study of current and previous AAS users to date, we have demonstrated robust functional brain connectivity reductions between major brain hubs modulating emotional and cognitive functions. Specifically, we have documented reduced connectivity between the DMN and the amygdala and between the DAN and a frontal node encompassing the SFG, IFG and the ACC in current users compared to non-users and previous users. The connectivity was further reduced in dependent users or those on cycle, showed a graded pattern of reductions when comparing subjects with low, medium and high lifespan exposure, and was negatively correlated with T/E ratio across the full sample.

Both theoretical considerations and empirical evidence suggest involvement of the amygdala as a hub mediating the adverse behavioral and emotional effects of AAS. However, sample sizes have been limited, which challenges the reliability of previous reports. Therefore, we applied a data driven approach, allowing detection of additional hubs beyond the amygdala, and assessment of anatomical specificity. In line with our hypotheses, we observed amygdala connectivity reduction in users, and further reductions with increased lifetime use and T/E ratio.

Despite the use of methods that are not necessarily directly comparable, our data-driven approach supports evidence from a small-scale study suggesting decreased functional connectivity between the amygdala and other brain regions in AAS users versus non-users ([@bb0185]). The findings are also in accordance with previous fMRI reports linking increases in testosterone levels to reductions in amygdala-prefrontal coupling ([@bb0270], [@bb0345], [@bb0375]), and reinforces the notion that testosterone fluctuations affect networks in the brain which are critically involved in emotional processing and regulation ([@bb0225], [@bb0275]).

The AAS effects on amygdala coupling are compatible with amygdala being among the brain regions with the highest androgen receptor mRNA density ([@bb0240], [@bb0245], [@bb0320]). AAS has been associated with a wide array of adverse effects on mental health and also cognitive deficits ([@bb0130], [@bb0180], [@bb0185], [@bb0350]). Perturbations of amygdala connectivity with cognitive and emotional network hubs including the DMN could potentially constitute brain correlates of these side effects.

In an overlapping sample it was recently reported smaller neuroanatomical volumes in AAS-users compared to non-users, including overall cortical, total gray matter, corpus callosum and putamen volumes and thinner cortex in widespread regions, including the posterior cingulate cortices, which are key regions in the DMN ([@bb0035]). Whereas DMN connectivity has been implicated in a range of psychiatric and neurological conditions ([@bb0045], [@bb0390]), suggesting that DMN connectivity is a sensitive but not specific index of brain function, our findings of reduced DMN-amygdala connectivity are in line with extant evidence of emotional dysregulation in AAS users.

The other edge showing reduced connectivity in AAS users implicated the DAN and the SFG/IFG/ACC. DAN, comprising key hubs in the intraparietal sulcus (IPS), superior parietal lobule (SPL), and the frontal eye field ([@bb0070]), constitutes a core attention node. The connectivity patterns of the DAN are predictive of cognitive load during a multiple object tracking ([@bb0005]), which supports its sensitivity to mental states associated with goal-driven attention. SFG constitutes a collection of distinct subregions in the prefrontal cortex, which has been implicated in a wide range of executive functions, including working memory and cognitive control ([@bb0080], [@bb0100]). The structural connectivity patterns of the anteromedial part of the SFG, which showed strongest loading in the implicated component, have been involved in response selection and cognitive and attentional control ([@bb0220]). The right IFG has consistently been implicated in response inhibition and impulse control ([@bb0020]), and damage of the right IFG are detrimental for stop-signal inhibition ([@bb0015]). Strikingly, activation of the right IFG was related to the speed of the inhibition process and use of illegal substances in a large sample of adolescents ([@bb0385]), and a single administration of testosterone altered the connectivity between the IFG and the ACC in healthy females ([@bb0040]). Although not representing a specific involvement ([@bb0380]), the critical role of the dorsal ACC in cognitive, motor and attentional control is well established ([@bb0050]), and along with implications of the dorsal ACC for reward-based decision-making ([@bb0055]), reduced connectivity with the DAN may reflect impaired coordinated neuronal processing related to cognitive control and impulsivity in AAS users. Our current findings are in line with a previous magnetic resonance spectroscopy (MRS) study reporting neurochemical abnormalities in the dorsal ACC in AAS users, likely reflecting increased glutamate turnover ([@bb0185]).

In contrast to the DMN-amygdala connection, the SFG/IFG/ACC-DAN edge was lower also in previous users compared to controls, and further reductions with increased dependency and lifetime exposure suggest an association with sustained use. This fits with the observation of reduced cognitive function after long-term use. Although further studies are needed to establish the reliability and state-dependency of these findings, they may suggest a chronic state conferring risk of long-term use and cognitive impairment.

In line with the state-dependency of functional imaging indices, the effects seems to be partly driven by current use, underscored by correlations between connectivity in both edges and T/E ratio, and the lack of differences between non-users and previous users on the amygdala-DMN edge. This could reflect the transient and state-dependent nature of resting state patterns, partly mediated by hormonal fluctuations. Typical AAS administration regiments results in highly non-physiological levels of androgens and their metabolites, and large fluctuations at different time points in the cycle. Hormonal fluctuations of this kind are likely to influence brain functions, and might explain AAS induced alterations in mood and behavior ([@bb0285], [@bb0350]).

This study does not come without limitation. First, the study design does not allow for claims regarding causality. In line with most observational and correlational studies, it is conceivable that predisposed variables conferring risk for AAS use (personality etc) may reflect confounding factors. Effects of such inherent associations should ideally be handled by design, e.g. by a prospective and randomized experimental study. Further, whereas the results suggest the involvement of selective large-scale brain functional networks, the neurobiological specificity of fMRI-based data is limited, which complicates a direct mechanistic interpretation. Indeed, the actions of AAS are complex and multifactorial, including both the described genomic effects but also additional non-genomic actions, estrogen receptor binding, and secondary modulatory effects on the hypothalamic-pituitary-adrenal (HPA) axis and influence of classical neurotransmitter and neuropeptide signaling. Further, the diversity of AAS effects on behavior reflects interactions between many factors, including predisposing vulnerability, age, sex, type(s) of AAS used, doses and method of administration ([@bb0250]). Although the observed correlations with T/E ratio suggest an acute effect of AAS, the associations with dependency and life time exposure also indicate a cumulative effect of sustained use. Further studies are needed to disentangle the acute and chronic influences of AAS use on brain and cognitive function, which is critical for informing predictive and prognostic models of the long-term impact of AAS use. In line with the reported sex differences in AAS use ([@bb0165], [@bb0295]), we included male subjects only. Further studies are needed to address the generalizability to the female population. Lastly, the consequences of AAS use are not confined to the brain. In particular, cardiovascular conditions, including hypertension, atherosclerosis and dyslipidemia, are substantial risks associated with AAS use ([@bb0370]). These cardiovascular risk factors could also influence the fMRI signal, which is modulated by complex neurovascular interactions ([@bb0230]), and future studies may be able to directly assess the common and unique effects on the brain and the cardiovascular system.

In conclusion, in the largest sample to date we have demonstrated reduced resting-state functional connectivity between brain network nodes critically involved in cognitive and emotional regulation, including the amygdala, the DMN, the DAN and SFG/IFG/ACC in AAS users. The brain connectivity findings are in line with the characteristic neuropsychiatric and cognitive consequences of sustained AAS use, including emotional and behavioral dysregulation. Associations with T/E ratio support sensitivity to current hormonal levels, and connectivity reductions with increased life time exposure and dependency suggest cumulative effects of sustained AAS use.
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![Results from the edgewise ANCOVA testing for differences between current AAS users, previous AAS users and controls. Fig. 1A: 49 edges showed nominal (p \< 0.05, uncorrected) and two edges showed significant (p \< 0.05, Bonferroni corrected) group effects, indicating reduced connectivity in links between the DMN and the amygdala, and between the DAN and SFG/IFG/ACC. Fig. 1B--C shows the mean connectivity within each of the groups for the two significant edges. Error bars denote standard error of the means (SEM).](gr1){#f0005}

![Edge connectivity stratified by clinical information. Fig. 2A: Mean connectivity for current AAS users with and without dependence. Fig. 2B: Mean connectivity for current AAS users by lifetime exposure (low dose, medium dose, high dose). Fig. 2C: Mean connectivity strength for current AAS users by cycle status (on/off). Error bars denote standard errors of the mean (SEM).](gr2){#f0010}

![Edge connectivity plotted as a function of T/E ratio across the full sample (n = 142).](gr3){#f0015}

###### 

Group comparisons on main attributes; demographic information, training information, drug and psychopharmaca use, emotional and behavioral problems.

Table 1

                                             Controls (n = 59)   Current AAS users (n = 50)   Previous AAS users (n = 16)                                               
  ------------------------------------------ ------------------- ---------------------------- ----------------------------- ------- ------- ------- -------- ---------- --------------------------------------------------------------------------
  Age (years)                                30.7                7.4                          33.6                          8.7     31.7    5.2     1.967    0.144      
  Education (years)                          15.9                2.7                          14.5                          2.6     14.2    1.9     5.230    0.007      a[⁎](#tf0005){ref-type="table-fn"}
  IQ                                         112.7               9.5                          105.9                         12.6    107.3   10.1    5.518    0.005      a[⁎⁎](#tf0010){ref-type="table-fn"}
  Height                                     180.7               6.5                          181.1                         6.9     180.5   6.9     0.084    0.920      
  Weight                                     90.2                14.5                         99.1                          12.0    93.9    15.4    5.737    0.004      a[⁎⁎](#tf0010){ref-type="table-fn"}
  BMI                                        27.6                4.0                          30.2                          3.6     28.7    4.0     6.243    0.003      a[⁎⁎](#tf0010){ref-type="table-fn"}
  Strength training/week (min)               477.3               247.4                        383.7                         217.4   223.3   123.2   8.600    \< 0.001   b[⁎⁎⁎](#tf0015){ref-type="table-fn"}, c[⁎](#tf0005){ref-type="table-fn"}
  Endurance training/week (min)              92.9                118.4                        115.8                         197.1   78.1    106.1   0.481    0.619      
  Cigarettes (day)                           0.4                 2.6                          1.8                           4.3     0.6     2.3     2.631    0.076      
  Alcohol units (week)                       3.5                 5.1                          1.6                           3.2     1.4     2.3     3.600    0.030      a[⁎](#tf0005){ref-type="table-fn"}
  Psychopharmaca (previous or current use)   n                   \%                           n                             \%      n       \%                          
   Antidepressants                           2                   3.4                          10                            20.0    3       18.8                        
   Anxiolytics                               0                   0.0                          7                             14.0    2       12.5                        
   Opioids                                   0                   0.0                          2                             4.0     0       0.0                         
   More than one sort                        0                   0.0                          3                             6.0     0       0.0                         
   None reported                             55                  93.2                         37                            74.0    11      68.8                        
  Emotional and problem behavior                                                                                                                                        
   Anxious/depressed                         52.2                4.3                          54.5                          6.7     58.6    9.0     6.300    0.003      b[⁎⁎](#tf0010){ref-type="table-fn"}
   Rule breaking behavior                    52.5                5.1                          59.3                          11.0    58.9    7.9     9.197    \< 0.001   a[⁎⁎⁎](#tf0015){ref-type="table-fn"}, b[⁎](#tf0005){ref-type="table-fn"}
   Internalizing problems                    45.9                9.9                          51.3                          11.0    56.3    13.3    5.958    0.004      a[⁎](#tf0005){ref-type="table-fn"}, b[⁎⁎](#tf0010){ref-type="table-fn"}
   Externalizing problems                    46.4                8.4                          55.0                          8.8     55.7    11.1    13.172   \< 0.001   a[⁎⁎⁎](#tf0015){ref-type="table-fn"},b[⁎⁎](#tf0010){ref-type="table-fn"}
   Total problems                            21.1                15.6                         33.8                          21.2    42.8    25.5    8.752    \< 0.001   a[⁎⁎](#tf0010){ref-type="table-fn"}, b[⁎⁎](#tf0010){ref-type="table-fn"}
  Tobacco                                    55.9                5.3                          54.1                          4.9     55.8    5.6     1.501    0.228      
  Alcohol                                    60.1                7.0                          56.8                          6.8     59.5    8.5     2.637    0.076      
  Drugs                                      51.4                7.0                          57.5                          12.9    56.6    9.8     4.564    0.013      a[⁎⁎](#tf0010){ref-type="table-fn"}

Bonferroni Post Hoc test a = control significantly different from current users, b = controls significantly different from previous users, c = current AAS users significantly different from previous AAS users.

p \< 0.05.

p \< 0.01.

p \< 0.001.
